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1. Introduction 
1.1 Insulin biosynthesis 
The islets of langerhans are the clusters of the endocrine tissue that scatter among the 
exocrine cells in the pancreas. The islets occupy approximately 1-2% of the total pancreatic 
tissue. Approximately, 1 million islets are scattered in the 25 cm long human pancreas. 
The insulin-producing cells make up 80% of each islet, while the remaining includes 
glucagon-producing -cells, somatostatin-producing -cells and the pancreatic 
polypeptide (PP) F-cells (Unger et al., 1978). Insulin is first synthesized as a 110-amino 
acid polypeptide chain known as pre-proinsulin. This precursor form contains a 
hydrophobic 24-amino acid at its N-terminus known as the signal peptide. This signal 
peptide is removed during translocation from the cytoplasm to the endoplasmic 
reticulum, producing the proinsulin which comprises of chains A, B and C with three 
disulfide bonds. Further proteolysis of proinsulin in the secretory vesicles by the 
prohormone convertases (PC1 and PC2) and the carboxypeptidase E, removes the C-
peptide from the rest of the molecule while still retains three disulfide bonds. This 
remaining part or mature insulin contains 21 amino acids on chain A and 30 amino acids 
on chain B (Steiner, 1969). 
1.2 Biphasic insulin secretion and insulin exocytosis 
The mature insulin is stored in the secretory granules which can be divided into two distinct 
pools, i.e. the reserve pool (RP) and the readily releasable pool (RRP) (Barg et al., 2002; 
Bratanova-Tochkova et al., 2002). The RRP is located close to the plasma membrane and is a 
rather small pool of insulin, comprising only 1-10% of total insulin in the cell. In contrast, the 
RP is located intracellularly and is a largest insulin pool. Once insulin granules in the RRP 
are released, the RP moves close to the plasma membrane to replenish the RRP (Barg et al., 
2002; Bratanova-Tochkova et al., 2002).  
Unlike other endocrine cells in the pancreas, -cells secrete insulin. This occurs not only 
under low glucose conditions (non-stimulatory conditions) (3-5 mM glucose) but also 
when the glucose concentration in plasma is high during the postprandial period (10-25 
mM glucose) when -cells secrete much larger amounts of insulin into the circulation. 
Although several nutrients including glucose, some amino acids and non-esterified fatty 
acids can stimulate insulin secretion, glucose appears to be the most potent insulin 
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secretagogue. The mechanism of glucose-induced insulin secretion (GSIS) is the most 
extensively studied. Secretion of insulin in response to the elevated levels of glucose in 
plasma is rapid and occurs in a two-step process known as biphasic insulin secretion 
(Straub and Sharp, 2002; Straub and Sharp, 2004). The first phase occurs very rapidly 
within a first few minutes upon stimulation. At this stage, the insulin granules in the 
RRP are fused very rapidly with the plasma membrane, resulting in a sharp release of 
insulin in the blood circulation. The first phase lasts only for a few minutes before the 
second phase begins and is sustained to the peak at 30-40 min or longer, depending on 
whether the concentration of plasma glucose is still high. The amount of insulin released 
during the second phase is much higher than the first phase. It is estimated that 99% of 
total insulin is secreted in this second phase, with an approximate release rate of 5-40 
granules/cell/minute (Barg et al., 2002; Straub and Sharp, 2004). Therefore the second 
phase of insulin secretion is more physiologically important. Not unexpectedly, this 
biphasic insulin secretion appears to be impaired in the patients with type 2 diabetes. 
The translocation of the insulin granules in the RP to become the RRP, as well as the 
docking of secretory vesicles to the plasma membrane are dynamic processes, requiring 
the rearrangement of cytoskeleton proteins inside the -cell (Wang and Thurmond, 
2009). During basal conditions, the F-actin filaments are polymerized as a dense network 
below the plasma membrane. This web structure of filamentous F-actin not only blocks 
the access of insulin granules in the reserved pool to the plasma membrane but also 
prevents the interaction of the v-SNARE protein, VAMP2, in the insulin granule vesicles 
with the t-SNARE proteins (syntaxin 1 and 4) on the plasma membrane. This process is a 
prerequisite for granule exocytosis. Under glucose stimulation conditions, F-actin 
filaments are depolymerized and there is an increased microtubule polymerization rate, 
allowing the RP of insulin granules to translocate to the plasma membrane where the 
interaction of vSNAREs and tSNAREs are maximized (Farshori and Goode, 1994; Howell 
and Tyhurst, 1979; Thurmond et al., 2003). 
2. Biochemical basis of glucose-induced insulin secretion 
2.1 KATP-dependent GSIS: Roles of glycolysis, mitochondrial metabolism and ATP-
sensitive potassium channels 
Unlike other ligands, glucose does not require a cellular receptor to mediate signal 
transduction to stimulate insulin secretion in -cells. This signal transduction is initiated 
by the rapid uptake of glucose through the glucose transporter 2 (GLUT2) in rodents 
(Chen et al., 1990) or glucose transporter 1 (GLUT1) in humans (De Vos et al., 1995) 
located on the plasma membrane of -cells. GLUT2 transporters allow the high-capacity 
and low affinity transport needed to equilibrate glucose concentrations across the plasma 
membrane and to support the -cell’s very high metabolic rate. Glucose then undergoes 
phosphorylation by a glucokinase which possesses a high Km for glucose, allowing the 
elevated levels of plasma glucose present during the postprandial period to enter -cells 
for glycolysis (Matschinsky, 1990). As glucokinase has low binding affinity for glucose, 
this means that the glycolytic rate is never saturated during the postprandial period. 
Because the -cell contains very low activity of lactate dehydrogenase, most glycolysis-
derived pyruvate enters the mitochondria and is oxidized to acetyl-CoA by the pyruvate 
dehydrogenease complex. Acetyl-CoA is then oxidized in the TCA cycle, concomitant 
with the production of the reducing equivalents, NADH. In contrast to other cell types, 
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-cells possess very high mitochondrial glycerol-3-phosphate dehydrogenase activity, 
which is a key enzyme in the mitochondrial-3-phosphate dehydrogenase shuttle 
(MacDonald, 1981). This allows NADH formed during glycolysis to be transported to the 
mitochondria for oxidative phosphorylation. The reducing equivalents obtained from 
glycolysis and TCA cycle are subsequently oxidized through the electron transport chain 
to produce cellular ATP. The key component that links the metabolic signal and the 
insulin granule exocytosis is the ATP-sensitive potassium channel (KATP). This channel is 
an octamer comprising four pore forming subunits of Kir6.2 and four subunits of the 
sulfonylurea receptor (SUR1) (Aguilar-Bryan et al., 1995). Under unstimulated 
conditions, KATP channels are opened, allowing the diffusion of K+ across plasma 
membrane of -cells near equilibrium. However, when the ratio of ATP:ADP ratio is high 
due to a high rate of glucose oxidation, ATP binds to the Kir6.2 component of the KATP 
channel, causing the channel to close. The depolarization of the membrane caused by the 
closure of the KATP channel opens the voltage-gated Ca2+ channel, causing Ca2+ influx 
into the cells (Ashcroft et al., 1984). This electrophysiological cascade results in the 
exocytosis of the insulin granues in the RRP. The increase of intracellular Ca2+ also 
stimulates the calmodulin-dependent protein kinase II which can phosphorylate several 
targets including the myosin light chain kinase that controls the cytoskeletal or secretory 
vesicle proteins (Easom, 1999). The insulin release triggered by the KATP-dependent 
mechanism corresponds to the first phase of the biphasic insulin secretion (Straub and 
Sharp, 2004).  
2.2 KATP-independent GSIS: Anaplerosis and coupling factors 
Although the KATP channel appears to control the GSIS, several lines of evidence suggest 
that GSIS can be operated independently of KATP channel. Treating -cells with a KATP 
channel opener, diazoxide, does not completely eliminate GSIS (Gembal et al., 1992). 
Furthermore, mice lacking Kir6.2 or the SUR1 component of KATP are still capable of 
secreting insulin in response to glucose albeit not as robust as the wild type mice 
(Seghers et al., 2000; Shiota et al., 2002). It has now become clear that GSIS requires 
“coupling factors” or “metabolic factors” that act as the amplifying signal of insulin 
secretion. Those coupling factors include NADPH, GTP, long chain acyl-CoA and 
glutamate. The biochemical pathways or cycles that lead to production of the coupling 
factors are described below. 
NADPH: The pentose phosphate pathway is the major pathway that produces NADPH, 
however the -cell does not possess glucose-6-phosphate dehydrogenase to produce this 
reducing equivalent. Instead, -cells possess a very high activity of pyruvate carboxylase 
and pyruvate dehydrogenase (MacDonald, 1993). Although equal proportions of the 
glycolysis-derived pyruvate enters mitochondria is carboxylated by PC and 
decarboxylated by pyruvate dehydrogenase, only the flux via the carboxylation reaction is 
correlated with GSIS (Lu et al., 2002). In -cells, there is a high rate of the export of TCA 
cycle intermediates, i.e. citrate and malate from mitochondria to cytoplasm which is 
known as cataplerosis (MacDonald, 2003). The exported citrate and malate are then 
recycled back to the mitochondria as pyruvate known as pyruvate cycling as shown in 
Figure 1. This pyruvate cycling can be shuttled to the pyruvate via pyruvate/malate, 
pyruvate/isocitrate or pyruvate citrate cycles (MacDonald et al., 2005). As noted in Figure 
1, NADPH is a common reducing equivalent produced by malate dehydrogenase, malic 
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enzyme and isocitrate dehydrogenase in the above three cycles, respectively. Pyruvate 
then re-enters the mitochondria and is carboxylated by pyruvate carboxylase, which is as 
highly abundant as in the gluconeogenic tissue. Deficiencies in pyruvate carboxylase, 
cytosolic malic enzyme and cytosolic isocitrate dehydrogenase result in impaired GSIS, 
indicating the importance of pyruvate cycling in -cells (Jitrapakdee et al., 2010). Glucose 
sharply increases the NADPH:NADP ratio proportion to the level of insulin secretion. The 
mechanism by which NADPH acts on insulin secretion is thought to be mediated through 
the glutaredoxin and thioredoxin redox pairs. The maintenance of the extra-mitochondria 
redox state via glutaredoxin and thioredoxin is required to support insulin granule 
exocytosis. Furthermore, NADPH is also associated with the voltage-dependent 
potassium channel (Kv) which works in an opposite way to the KATP channel. This channel 
functions as K+ efflux, causing the repolarization of the -cell plasma membrane for the 
next cycle of GSIS. Binding of NADPH to the Kv causes the conformational change of its 
regulatory subunit, reducing the efficacy of this channel for repolarization of the -cell 
plasma membrane and enhancing the action of KATP channel [reviewed by Jitrapakdee et 
al., 2010]. 
Long chain acyl-CoA: Long chain acyl-CoA is another coupling factor thought to be 
required for GSIS (Brun et al., 1996; Corkey et al., 1989; Prentki et al., 1992). Evidence for this 
is derived from the following observations. Acute exposure of -cells to glucose sharply 
increases intracellular levels of malonyl-CoA and long chain acyl-CoA. In supporting this 
observation, exposure of permeabilized -cells to long chain acyl-CoA or non-esterified fatty 
acids also stimulates Ca2+-evoked insulin exocytosis. This is accompanied by elevated levels 
of acetyl-CoA carboxylase 1 (ACC1), a rate-limiting enzyme of de novo fatty acid synthesis. 
ACC condenses two molecules of acetyl-CoA to malonyl CoA and this enzyme is rapidly 
induced by high concentrations of glucose in -cells. Because malonyl-CoA is a potent 
inhibitor of the carnitine palmitoyl transerase I (CPT-1), the rapid increase of malonyl-CoA 
level by ACC1 would inhibit -oxidation of fatty acids, resulting in the elevated levels of 
long chain acyl-CoA in -cells (Brun et al., 1996; Corkey et al., 1989; Prentki et al., 1992). This 
long chain acyl-CoA can be used as the precursor for synthesizing diacyl glycerol and 
phospholipids. Consistent with this idea, acute exposure of -cells to glucose also modifies 
the concentrations of phospholipids and cholesteryl esters. These modifications could affect 
membrane fluidity and exocytosis of the secretory vesicles. Furthermore diacyl glycerol can 
also activate protein kinase C which in turn phosphorylates its downstream targets 
including ion channels.  
Although inhibition of ACC1 and fatty acid synthetase activities result in a marked 
reduction of GSIS, suppression of ATP-citrate lyase expression does not appear to affect 
GSIS, suggesting the presence of another pathway that can supply acetyl-groups for de novo 
fatty acid synthesis in -cells [reviewed by Jitrapakdee et al., 2010]]. An alternate pathway 
that provides acetyl-groups for long chain acyl-CoA synthesis lies within the acetoacetate 
production catalyzed by acetoacetyl-CoA synthetase. This was demonstrated by the 
knockdown experiment in which suppression of this enzyme expression impairs GSIS in -
cells (MacDonald et al., 2005). Acute exposure of -cells to glucose not only stimulates rapid 
lipogenesis but also alters phospholipid and cholesteryl ester contents in the plasma 
membrane which in turn affects insulin granule exocytosis and -cell plasma membrane 
fluidity (MacDonald et al., 2008).  
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Fig. 1. Biochemical basis of glucose-induced insulin secretion (GSIS). Glucose enters -cells 
through GLUT2 transporter and is metabolized to pyruvate by glycolysis. Pyruvate enters 
the mitochondria where it is oxidized in the TCA cycle. The NADH produced by both 
glycolysis and TCA cycle are oxidized to produce the cellular ATP. The increased level of 
ATP:ADP triggers the closure of ATP-sensitive potassium channels resulting in membrane 
depolarization. This in turn opens the voltage gate-dependent Ca2+ channels, causing the 
influx of Ca2+ which triggers the immediate exocytosis of insulin granules in the readily 
releasable pool, corresponding to the 1st phase of biphasic insulin secretion. Some 
components of the TCA cycle, i.e. malate, citrate and isocitrate are also exported from the 
mitochondria to cytoplasm (cataplerosis) where these exported products are converted back 
to pyruvate (pyruvate cycling) concomitantly with the production of NADPH via pyruvate-
malate, pyruvate-citrate and pyruvate-isocitrate shuttles, respectively. PC replenishes OAA 
in the TCA cycle when malate, citrate and isocitrate are removed for the pyruvate cycling. 
The exported citrate is converted to oxaloacetate and acetyl-CoA. ACC1 converts acetyl-CoA 
to malonyl-CoA which is subsequently converted to long chain acyl-CoA by FAS. The 
NADPH malonyl-CoA, long chain acyl-CoA together with the mitochondrial GTP produced 
by succinyl-CoA synthetase and glutamate produced by glutamate dehydrogenase serve as 
“amplifying signals” that correspond to the 2nd phase of biphasic insulin secretion. ACC, 
acetyl-CoA carboxylase; ACL, ATP-citrate lyase; cICD, cytolsolic isocitrate dehydrogenase; 
CIC, citrate/isocitrate carrier; GTP-SC, GTP-succinate dehydrogenase; FAS, fatty acid 
synthase, MDH, malate dehydrogenase; ME, malic enzyme, PC, pyruvate carboxylase; PDH, 
pyruvate dehydrogenase complex; RP, reserve pool; RRP, readily releasable pool. 
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Other coupling factors: Acute exposure of -cells to glucose causes a sharp increase in the 
level of glutamate, suggesting that glutamate might be a second messenger that promotes 
insulin secretion (Maechler and Wollheim, 1999). This intracellular source of glutamate is 
derived from the conversion of -ketoglutarate by the glutamate dehydrogenase. Although 
there is a strong correlation between the rapid increase of an intracellular level of glutamate 
upon an acute stimulation by glucose, there is no direct evidence indicating that the rise of 
glutamate level results in the insulin secretion (MacDonald and Fahien, 2000). Incubation of 
-cells with glutamine, a precursor of glutamate production does not increase GSIS. 
Furthermore the GDH ablated mice showed only 30-40% loss of GSIS indicating that 
glutamate may not be the second messenger for insulin secretion (Carobbio et al., 2009).  
The level of mitochondrial GTP may be one of the coupling factors that regulate GSIS. The 
succinyl-CoA synthetase catalyzes the conversion of succinyl-CoA to succinate, concomitant 
with the production of GTP. Suppression of the succinyl-CoA synthetase expression results 
in impaired GSIS in -cells, indicating the importance role of mitochondrial GTP in GSIS 
(Kibbey et al., 2007). 
Incubation of -cells with high concentrations of glucose not only stimulates ATP 
production via electron transport system but also triggers the production of the reactive 
oxygen species in the mitochondria. There is evidence that the reactive oxygen species may 
be an obligatory signal for insulin secretion (Leloup et al., 2009; Pi et al., 2007). Incubation of 
-cells with certain reactive oxygen species stimulates insulin secretion. Because these 
reactive oxygen species are toxic to the cells and they are removed very quickly by the 
antioxidant enzymes in the -cells the question remains whether this transient increase of 
reactive oxygen species is a bona fide coupling factor for GSIS. 
3. Other insulin secretagogues 
Although glucose is the most potent insulin secretagogue, certain amino acids including 
leucine and glutamine can also stimulate insulin secretion (Fahien et al., 1988; Malaisse-
Lagae et al., 1982). Leucine stimulates insulin secretion because its acts as an allosteric 
activator of the glutamate dehydrogenase, an anaplerotic enzyme that converts glutamate to 
-ketoglutarate in the TCA cycle. Glutamine by itself cannot stimulate insulin secretion, 
however combination of glutamine and leucine stimulates insulin secretion as robustly as 
glucose because glutamine can be converted to glutamate, and leucine acts as allosteric 
activator of glutamate dehydrogenase in the presence of excess glutamate substrate. Unlike 
leucine, arginine can stimulate only the 1st phase but not the amplifying phase of insulin 
secretion. The reason for this is because arginine is not metabolized in the mitochondria in 
the glycolysis or TCA cycle. 
Free fatty acids by themselves cannot stimulate insulin secretion but low concentrations of 
them augment glucose-induced insulin secretion (Deeney et al., 2000; Poitout, 2003). Free 
fatty acids can be metabolized to long chain fatty acyl-CoA which is one of the coupling 
factors as described earlier. However, chronic exposure of -cells to high concentration of 
fatty acids promotes -cell apoptosis via the formation of ceramides or other reactive lipids 
(Giacca et al., 2011; Poitout and Robertson, 2002). 
Apart from the nutrient secretagogues, some hormones can stimulate insulin secretion. The 
well known insulinotropic peptide hormones include the glucagon-like-peptide-1 (GLP-1) and 
gastic-inhibitory peptide (GIP) (Holst, 2007). GLP-1 is secreted from the enteroglucagon-
www.intechopen.com
 Insulin Secretion and Actions 
 
9 
producing cells (L-cells) in the lower intestine, while GIP is secreted from K-cells in the upper 
gastrointestinal tract. These two peptides are secreted in response to the ingestion of glucose. 
GLP-1 acts to increase insulin secretion via the circulation acting directly on pancreatic  cells 
and also via the sensory afferent neurons acting on the central nervous system (Holst et al. 
2007). In the brain GLP-1 acts a neuropeptide to promote neuroendocrine actions on the 
autonomic nervous system including regulation of food intake, satiety and pancreatic 
secretions. GLP-1 is controlled by the dipeptidyl protease 4 (DPP4). DPP4 cleavage renders 
GLP-1 unable to bind to its target receptor, the glucagon-like peptide-1 receptor (GLP-1R) and 
thus tightly controls the levels of GLP-1 in the intestine and the circulation. GLP-1 also 
promotes metabolic control by inhibiting glucagon secretion.  
4. Insulin oscillation 
In humans, mouse and rat the majority of insulin (>70%) is released in a pulsatile manner 
with a periodicity of 3-5 min (Matveyenko et al., 2008; Porksen et al., 1997; Song et al., 2000). 
This pattern is observed both before and after meals, however the amplitude of oscillation is 
higher during the postprandial period. The oscillation of insulin secretion is believed to be a 
mechanism to prevent down-regulation of insulin receptors in the target tissues. The 
pulsatile insulin secretion is most obviously detected in the portal vein and can also be 
detected in the isolated islets. Remarkably, the oscillations of insulin secretion are also 
synchronized among one million islets. These tightly synchronized oscillations require the 
complex factors including the soluble factor, gap junction and intra-pancreatic nerves. 
However, this pulsatile pattern becomes less obvious in the peripheral blood (Tengholm 
and Gylfe, 2009). These oscillations are intrinsic to the islets, and are regulated by the 
concentrations in individual -cells of cytoplasmic Ca2+, intracellular cAMP and plasma 
membrane phosphoinositide lipids, as well as the activity of phospholipase C (Tengholm 
and Gylfe, 2009). The oscillations of insulin secretion from pancreatic islets correlate very 
well with the oscillation of intracellular Ca2+ concentration (Bergsten et al., 1994; Bergsten 
and Hellman, 1993). Although it is widely accepted that the insulin oscillation is the result of 
intracellular Ca2+ oscillation, it is unclear whether the oscillation of Ca2+ levels results from 
the oscillations of glycolytic and/or mitochondrial intermediates. The oscillation of 
phosphofructokinase (PFK) activity is well known to produce the oscillation of its product, 
fructose-1,6-bisphosphate which may in turn regulate oscillation of intracellular Ca2+ 
concentrations (Tornheim, 1997). However, suppression of PFK activity in -cells did not 
affect the oscillation of intracellular Ca2+ concentration, suggesting that oscillation of PFK 
activity may not control the pulsatile manner of insulin secretion. However, recent reports 
reports have shown that there are oscillations of key metabolic products in the mitochondria 
including citrate, ATP, NAD(P)H, and O2 consumption (Bertram et al., 2007; Tengholm and 
Gylfe, 2009). Notably, the oscillations of these metabolic products are also in the same range 
as that of intracellular Ca2+ oscillation. Although the oscillations of key products of 
mitochondrial metabolism are likely to regulate the oscillations of intracellular Ca2+, Ca2+ by 
itself may feedback inhibit or stimulate the mitochondrial metabolism, resulting in the 
decrease or increase insulin secretion. The intracellular Ca2+ raised upon glucose-induced 
insulin secretion can enter mitochondria via the uniporter and depolarize the 
electrochemical potential in the inner membrane of the mitochondria thereby reducing 
mitochondrial ATP production (Bertram et al., 2007; Tengholm and Gylfe, 2009). However, 
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the intra-mitochondrial Ca2+ can also stimulate the activities of several mitochondrial 
enzymes including the pyruvate dehydrogenase complex, isocitrate dehydrogenase and -
ketoglutarate dehydrogenase (Bertram et al., 2007; Tengholm and Gylfe, 2009). These 
synchronous oscillations of products of mitochondrial metabolism are believed to 
orchestrate the oscillation of insulin secretion.  
Normoglycaemia is more efficiently maintained when insulin is delivered in a pulsatile 
fashion, most probably because of enhanced expression on the target tissues of insulin 
receptors that have a similar recycling periodicity. Significantly, this pulsatile delivery of 
insulin is lost or severely diminished in type 2 diabetes. This contributes to insulin resistance 
and the requirement for compensatory hypersecretion by the islets, potentially leading to 
their exhaustion (Bertram et al., 2007; Tengholm and Gylfe, 2009).  
5. Insulin signaling 
Insulin signaling controls metabolism as well as growth and survival in many mammalian 
tissues. It also plays a vital role in controlling lifespan (Longo et al., 2008). In humans, 
perturbation of insulin signaling results in diabetes but is also implicated in neoplasia 
(Pollak, 2008). Signaling via the insulin receptor (IR) results in activation of two main 
signalling pathways: the phosphoinositide 3-kinase/Akt (PI3K/Akt) and the mitogen 
activated protein kinase (MAPK) pathways. Both mitogenic and metabolic signalling 
outcomes are activated via the IR and the response arising depends on expression levels of 
the receptor and downstream signaling molecules by the cells within the target tissues.  
The IR exists in two isoforms arising from alternative splicing (Belfiore et al., 2009; Denley et 
al., 2003). The exon 11+ (IR-B) isoform is expressed in insulin sensitive tissues and primarily 
in the liver. This receptor is responsible for the metabolic control processes classically 
associated with insulin’s action. The exon 11- (IR-A) isoform, which lacks the 12 amino acids 
normally encoded by exon 11, is expressed mainly in fetal tissues including liver, kidney 
and muscle. Interestingly, both insulin and insulin-like growth factor-II (a structurally 
related mitogenic growth factor) can bind to the IR-A with high affinity to promote cell 
proliferation and survival. The foetal co-expression of IGF-II and IR-A suggests both may 
act together to play an important role in foetal growth. Interestingly, expression of both IGF-
II and the IR-A is often upregulated in cancer and this represents an additional mechanism 
by which cancer cells grow and survive (Avnet et al., 2009; Denley et al., 2003). 
5.1 Insulin receptor structure 
The IR is a transmembrane glycoprotein with tyrosine kinase activity. It is a homodimer 
with each subunit consisting of an extracellular  subunit and a transmembrane spanning 
subunit (see Figure 2) (De Meyts and Whittaker, 2002; Ward and Lawrence, 2009). The 
receptor is produced from a single proreceptor protein that is glycosylated, dimerised and 
proteolytically processed into separate  (~135kDa) and  chains (95kDa, mature receptor 
~460kDa). The ligand binding region is located in the extracellular subunits and the 
tyrosine kinase domain is located in the cytoplasmic region of the subunits. The 
stoichiometry of ligand binding is 1:1. A recent crystal structure of the extracellular portion 
of the IR revealed a folded over conformation with two potential ligand binding pockets 
(McKern et al., 2006; Smith et al., 2010). The residues important for ligand binding have been 
identified by a series of detailed site-directed mutagenesis studies, with the use of IR:IGF-1R 
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chimeras and using antibody competition for ligand binding (De Meyts and Whittaker, 
2002). Within a single binding pocket ligand contacts the receptor at two sites. Site 1 is made 
up of residues within the L1 domain (large domain 1 leucine rich region) and ID (insert 
domain), with each derived from opposite receptor monomers. Site 2 is located within the 
Fn-III-1 and Fn-III-2 domains (derived from the same monomer as the ID of site 1).  
 
 
Fig. 2. The IR structure. The IR consists of 2  and intracellular subunits made up of the 
following domains (labelled on one receptor monomer, Left): L1 and L2, large domains 1 
and 2 (leucine-rich repeats); CR, Cys-rich domain; Fn1, Fn2, Fn3, fibronectin type III 
domains 1-3 (also referred in the text as FnIII-1, FnIII-2, FnIII-3); ID, insert domain; Ex11, 12 
residues encoded by exon11 (IR-B only); TM, transmembrane; JM, juxtamembrane; TK, 
tyrosine kinase; CT, C-terminal domains (adapted from Denley et al., 2003). The ligand 
binding regions are found in the L1, Fn1 and Fn2 (also referred in the text as FnIII-1 and -2) 
and the ID. (Right) The folded over conformation of the receptor is revealed in the IR 
ectodomain crystal structure (McKern et al., 2006), pdb 3LOH). The two binding pockets 
evident in the folded over structure include residues from each receptor monomer. One 
monomer is depicted in ribbon mode and the other is in surface filled mode. 
While there is currently no structure of insulin bound to the intact IR, chemical cross-linking 
data and the structure of the IR ectodomain have allowed the development of a structural 
model of the interaction (Lou et al., 2006). Ligand binding cross-links the two receptor 
monomers leading to a structural change in the ectodomain and precluding binding of a 
second ligand molecule in the unoccupied binding pocket (as described in the mathematical 
model by Kiselyov et al., (Kiselyov et al., 2009).  
The receptor structural change is transduced across the transmembrane region to the 
intracellular domain leading to activation of the intracellular tyrosine kinase domain. Crystal 
structures of the inactive and activated forms of the IR tyrosine kinase domain reveal that the 
first step in the activation process is the movement of an inhibitory arm reaching from the juxta 
membrane region that maintains the tyrosine kinase domain in a basal, low activity state. 
Removal of juxtamembrane domain Tyr984 from its contacts with the amino terminal kinase 
lobe allows coordination of ATP and subsequent trans autophosphorylation of Tyr1146, 
Tyr1150 and Tyr1151 within the activation loop of the tyrosine kinase domain (Hubbard, 2004).  
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5.2 Insulin signaling components 
Following tyrosine kinase domain activation several other residues are phosphorylated and 
these act as docking sites for downstream signaling molecules (Siddle, 2011; Taniguchi et al., 
2006). In fact at least 7 tyrosine residues, 12 serine residues and a single threonine have been 
shown to be phosphorylated in response to insulin (Kohanski, 1993; Lewis et al., 1990; Tavare 
and Denton, 1988; Tornqvist et al., 1987). Initial autophosphorylation of Tyr960 within a NPXY 
motif of the transmembrane domain provides an important docking site for insulin receptor 
substrate 1 and 2 (IRS-1 and IRS-2) and Shc (both substrates for the IR tyrosine kinase). The 
Grb2-associated binder 1 (Gab 1) and Cas-Br-M (murine) ecotropic retroviral transforming 
sequence homologue (Cbl) proteins also are substrates of the IR tyrosine kinase and play a role 
in glucose uptake (see section 6.1). IRS-1 and IRS-2 contain a phosphotyrosine-binding domain 
and a plekstrin-homology domain which facilitate the interaction with activated IR via 
phosphoTyr960. IRS and Shc proteins are phosphorylated on multiple sites by the IR and these 
phosphotyrosines then act as docking sites for different SH2 containing signaling molecules 
including PI3K and growth receptor binding protein-2 (Grb2). These proteins are the first 
molecules of the two main insulin stimulated signaling cascades: the PI3K-AKT/protein 
kinase B (PKB) pathway, which leads to protein translation, metabolic control, cell cycling and 
cell survival, and the Ras-mitogen-activated protein kinase (MAPK) pathway, which controls 
cell growth and differentiation.  
There are six IRS proteins with IRS-1 and IRS-2 being the most widely expressed (Taniguchi 
et al., 2006). Knockdown studies in vivo and in vitro indicate that IRS-1 and IRS-2 play 
different roles of in insulin signaling. For example, in vivo knockdown of hepatic IRS-1 
expression is associated with increased gluconeogenesis whereas down-regulation of 
hepatic IRS-2 is associated with expression of genes involved in lipogenesis. IRS-1 knockout 
mice are small and insulin resistant with normal glucose homeostasis due to compensatory 
insulin secretion. IRS-2 knockout mice are normal in size but develop diabetes and are 
insulin resistant due to reduced -cell mass (reviewed in (Taguchi and White, 2008)). 
Although they do recruit many of the same binding partners the signalling differences of the 
two IRS isoforms may be explained by their differing abilities to bind certain downstream 
signalling molecules. Subcellular localisation or activation kinetics may also play a role. IRS 
signalling is controlled by feedback mechanisms predominantly involving serine 
phosphorylation of the IRS proteins by downstream kinases including Akt, S6K1 and GSK3, 
and leading to IRS inactivation (Taniguchi et al., 2006).  
Several proteins regulate signaling via the IR (Taniguchi et al., 2006). SOCS-3 (suppressor of 
cytokine signalling-3), induced by cytokine signaling, regulates IR signaling by competing 
for binding with IRS proteins to phosphorylated Tyr960, thereby down-regulating insulin’s 
action. SOCS proteins have attracted significant interest as they are up-regulated in cases of 
insulin resistance. Growth factor receptor bound proteins (Grb10/Grb14) act as pseudo 
substrates for the tyrosine kinase domain of activated IR and thereby inhibit further 
phosphorylation of downstream signaling molecules including IRS-1. They also protect the 
phosphotyrosines in the tyrosine kinase domain from dephosphorylation by phosphatases, 
thus potentially prolonging receptor activation (Holt and Siddle, 2005). One such 
phosphatase is PTP1B, which directly interacts with the IR tyrosine kinase domain thereby 
reducing IR signalling activity (Yip et al., 2010). Grb10 also promotes receptor 
downregulation via its interaction with the ubiquitin ligase NEDD4 (Ramos et al., 2006; 
Vecchione et al., 2003). Simultaneous knockout of Grb10 and Grb14 improved glucose 
homeostasis due to enhanced IR signalling (Holt et al., 2009; Holt and Siddle, 2005).  
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Fig. 3. The canonical insulin receptor signalling pathways (PI3K/AKT and MAPK pathways). 
Binding of insulin (INS) to the insulin receptor (IR) leads to activation of the intracellular 
receptor tyrosine kinase. Subsequent autophosphorylation leads to recruitment of IRS-1/2 and 
Shc. Activated PI3K then converts phosphotidyl inositol (4,5) bisphosphate (PIP2) to 
phosphotidyl inositol (3,4,5) trisphosphate which then recruits PDK and AKT to the membrane. 
AKT is phosphorylated on Thr308 by PDK and Ser473 by mTORC2. There are many target 
substrates of the serine kinase AKT including TSC1/2, which when phosphorylated by AKT 
becomes inactive and thereby promotes activation of the mTORC1 complex and subsequent 
protein synthesis. Inactivation of the GTPase activating protein AS160 by AKT relieves the 
inhibition of RAB GTPase to promote GLUT4 translocation and glucose uptake. Glycogen 
synthase promotes glycogen synthesis when AKT inactivates GSK3 and phosphorylation of 
FOXO1 prevents its translocation to the nucleus and thus inhibits gluconeogenesis. AKT 
signalling is switched off by the phosphatases PTEN (converts PIP3 to PIP2) and PTP1B (direct 
action on the IR). Mitogenic signalling involves recruitment of Grb2 by activated IRS-1/2 and 
Shc. SOS bound to Grb2 acts as a guanine exchange factor promoting the formation of active 
RAS GTP. Activation of RAF and the downstream MAPK signalling cascade follows leading to 
activation of p90RSK and protein synthesis as well as the transcription factors Elk-1 and c-FOS. 
IRS proteins are negatively regulated upon serine phosphorylation by AKT, mTORC1, pS6K 
and activated ERK1/2. Activation is indicated by a solid line and inhibition by a dashed line. 
IRS, insulin receptor substrate; PI3K, phosphotidylinositol 3-kinase; PDK, protein dependent 
kinase; mTORC, mammalian target of rapamycin complex; PTEN, phosphatase and tensin 
homologue; FOXO1, forkhead box O1; GSK3, glycogen synthase kinase 3; GS glycogen 
synthase; AS160, AKT substrate of 160kDa; TSC1/2, tuberous sclerosis complex-1 and -2; Rheb, 
Ras homologue enriched in brain; Raptor, regulatory associated protein of mTOR; PTP1B, 
protein tyrosine phosphatase 1B; Grb2, growth receptor binding protein 2; SOS, son-of-
sevenless; MEK, MAPK kinase; ERK, extracellular signal-regulated kinase 1 and 2; p90RSK, p90 
ribosomal protein S6 kinase; pY, phosphotyrosine; pS, phosphoserine; pT, phosphothreonine.  
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Activation of the IR by insulin also leads to internalization of the ligand:receptor 
complex and results in endosomal breakdown of insulin. Internalised receptor is either 
degraded or recycled back to the membrane for further signaling events (Foti et al., 
2004). Interestingly, rapid receptor recycling is linked to sustained Akt signalling 
(Romanelli et al., 2007), whereas there is evidence that receptor internalization plays a 
role in prolonged signalling associated with the MAPK pathway and mitogenic activity 
(Jensen et al., 2007). 
6. Insulin actions 
6.1 Mitogenic effects 
Insulin receptor signaling via the MAPK pathway leads predominantly to mitogenic 
biological effects such as cell growth, survival and differentiation (Belfiore et al., 2009; 
Siddle, 2011). Binding and activation of IRS proteins leads to recruitment of Grb2 and the 
guanyl nucleotide exchange factor SOS (son-of-sevenless). SOS then activates the small 
GTPase Ras which in turn activates Raf and the MAPK, MEK and Erk1/2 signaling 
cascade. Activated Erk1/2 phosphorylates a series of targets including p90 ribosomal 
protein S6 kinase (p90RSK), which promotes protein synthesis, and the transcription 
factors Elk-1 and c-Fos (Figure 3) (Shaul and Seger, 2007). Erk1 and Erk2 have both 
overlapping and unique functions. Erk1 knockout mice develop normally and are born a 
normal size probably due to compensation by Erk2. However, Erk1 knockouts do have 
deficient thymocyte maturation and some neurological defects. In contrast knockout of 
Erk2 is embryonic lethal. In relation to metabolism, Erk1 appears to play specific roles in 
adipogenesis (Taniguchi et al., 2006).  
While insulin stimulates mitogenic effects such as promoting pancreatic  cell health 
through signalling via the IR (Belfiore et al., 2009), it is also able to activate mitogenic 
pathways upon binding to the highly similar type 1 IGF receptor (IGF-1R) (Pollak and 
Russell-Jones, 2010). IGFs promote cell proliferation, survival and migration upon 
activation of the IGF-1R. IGFs are essential for normal growth and development and also 
promote cancer cell proliferation and survival. Elevated circulating IGF-I levels have been 
associated with an increased risk of cancer and up-regulation of IGF-I, IGF-II and the IGF-
1R is commonly seen in many types of cancer (Pollak, 2008). The affinity of insulin for the 
IGF-1R is at least 100-fold lower than the affinity of IGF-I for its receptor. Therefore 
activation of the IGF-1R by insulin only occurs in situations of high insulin concentrations. 
For this reason there is growing concern that hyperinsulinemia associated with Type 2 
diabetes leads to an elevated risk of cancer, highlighting the need for tight glucose control 
in these patients. Furthermore the potential increased cancer risk is being assessed for 
patients currently treated with long acting insulin mimetics such as glargine which have 
increased IGF-1R binding affinities (Pollak and Russell-Jones, 2010).  
6.2 Metabolic effects 
Insulin exerts its metabolic effects in three major tissues including liver, skeletal muscle and 
adipose tissues. Those effects include the stimulation of glucose transport, glycolysis, 
lipogenesis and protein synthesis while inhibiting gluconeogenesis, glycogenolysis, lipolysis 
and protein breakdown (see Figure 4). 
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Fig. 4. Metabolic effects of insulin in liver, adipose tissue and skeletal muscle. In liver, 
insulin stimulates glycogenesis, glycolysis and lipogenesis (de novo fatty acid synthesis) but 
inhibits glycogenolysis and gluconeogenesis. In muscle, insulin stimulates glucose uptake 
via GLUT4 transporter, glycogenesis and protein synthesis but inhibits protein breakdown 
and glycogenolysis. In adipose tissue, insulin stimulates glucose uptake via GLUT4, 
lipogenesis (de novo fatty acid synthesis), and triglyceride synthesis by stimulating LPL 
activity. -, inhibition; +, stimulation.  
6.2.1 Glucose transport 
Glucose transporter 4 (GLUT4) is the most abundant transporter isoform in adipocytes 
and myocytes and is the only isoform that is regulated by insulin (Bryant et al., 2002). 
GLUT4 acts as the gate that allows extracellular glucose to enter the cells. During nutrient 
restriction or unstimulated conditions, 5-10% of GLUT4 is located on the plasma 
membrane while 90-95% is sequestered in an intracellular vesicle-bound form. However, 
when the concentration of extracellular glucose becomes high and the insulin is released, 
GLUT4 is translocated from intracellular sites to the plasma membrane (Holman and 
Cushman, 1994). The molecular mechanism by which insulin promotes the translocation 
of GLUT4 depends upon phosphorylation of downstream kinases including PI3K and 
Akt. The production of phosphoinositol(3,4,5) triphosphate by PI3K  facilitates the release 
of the vesicle-bound GLUT4 and allows trafficking to the cell surface. The increased 
phosphoinositol (3,4,5)-triphosphate also promotes actin polymerization, resulting in the 
mobilization of the vesicle-bound GLUT4 near the plasma membrane. The other signal 
that promotes translocation of GLUT4 involves phosphorylation of Cbl that is associated 
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with an adaptor protein, CAP. The CAP-phosphorylated Cbl complex is then translocated 
to the lipid raft on the plasma membrane where this complex further interacts with three 
more adaptor proteins, namely Crk, C3G and TC10. Here, TC10 functions as the second 
signal independent of PI3K activation, facilitating the trafficking of GLUT4 to the plasma 
membrane. Furthermore, fusion of the vesicle bound GLUT4 to the plasma membrane 
also requires the interaction between SNARE on the GLUT4 vesicles and the plasma 
membrane (Huang and Czech, 2007; Ishiki and Klip, 2005; Shisheva, 2008). The 
translocation of GLUT4 to the plasma membrane occurs within a few minutes after insulin 
stimulation and this allows rapid uptake of extracellular glucose to the muscle cells. In 
fact 75% of insulin-dependent glucose disposal occurs through GLUT4-mediated 
transport into muscle cells.  
6.2.2 Glycogen synthesis 
Glycogenesis is an important means to store excess glucose in liver and skeletal muscle 
(Pagliassotti and Cherrington, 1992). Insulin stimulates glycogen synthesis in liver and skeletal 
muscle through the glycogen synthase kinase 3 (GSK3). There are two isoforms of GSK3, i.e. 
GSK3 (51 kDa) and GSK3 (47 kDa), both of which share over 98% sequence identity in their 
kinase domains but different in their N-termini (Forde and Dale, 2007). Both isoforms are 
capable of phosphorylating glycogen synthase. During starvation when glucose is low, 
glycogen synthase is phosphorylated by casein kinase II at Ser657. Phosphorylation at this 
residue of glycogen synthase primes GSK3 to phosphorylate three more serine residues 
namely, Ser641, Ser645 and Ser649, making glycogen synthase becomes catalytically inactive 
(Forde and Dale, 2007). However, when insulin is released in response to hyperglycemic 
conditions, this leads to the activation of the Akt/PKB signaling cascade as mentioned earlier. 
Akt/PKB in turn phosphorylates Ser21 residue of GSK or Ser9 residue of GSK3, causing 
them become catalytically inactive, and no longer able to phosphorylate glycogen synthase 
(Sutherland et al., 1993). The non-phosphorylated glycogen synthase can now convert the 
UDP-glucose into glycogen in muscle and hepatocytes. Insulin also stimulates the activity of 
protein phosphates 1 (PP1) specifically localized near the glycogen granules (Brady and Saltiel, 
2001; Ragolia and Begum, 1998). This enzyme removes a phosphate group from glycogen 
synthase, rendering it catalytically active.  
Insulin not only stimulates glycogen synthesis but also inhibits the process of glycogen 
breakdown known as glycogenolysis which is important for the supply of glucose during 
short term starvation. Glycogen phosphorylase releases one unit of glucose in the form of 
glucose-1-phosphate from the glycogen chain. During starvation when the level of glucagon 
is high, binding of glucagon to its G-protein couple receptor activates adenylyl cyclase 
activity to convert ATP to cAMP. cAMP in turn stimulates PKA activity to phosphorylate an 
inactive form of glycogen phosphorylase (known as the phosphorlyase b form), 
transforming it to become an active form (glycogen phosphorylase a form) (Johnson, 1992). 
However, during postprandial period when the level of insulin is high, insulin activates 
phosphodiesterase which subsequently converts cAMP to AMP. As the level of cAMP is 
low, PKA is no longer activated, the glycogen phosphorylase remains in an inactive form. 
Furthermore, insulin activates protein phosphatase-1 to remove phosphate from 
phosphorylase a, transforming it to an inactive form and results in the inactivation of 
glycogenolysis (Brady and Saltiel, 2001; Ragolia and Begum, 1998). 
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6.2.3 Gluconeogenesis 
Gluconeogenesis is the pathway that converts non-carbohydrate precursors including 
glycerol (product from triglyceride hydrolysis), lactate (end product from anaerobic 
glycolysis in skeletal muscle) and alanine (from protein breakdown in muscle) to glucose 
through the combined reverse reactions of glycolysis and the four additional reactions 
catalyzed by pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose-1,6-
bisphosphatase and glucose-6-phosphatase, respectively (Pilkis and Granner, 1992). 
Gluconeogenesis is absolutely essential for survival during prolonged fasting because red 
blood cells and the brain primarily rely on glucose as fuel. The genes encoding these four 
enzymes are regulated by two transcription factors, i.e. the forkhead transcription factor box 
O (FoxO) and the cAMP-responsive element binding protein (CREB). During prolonged 
starvation, glucagon triggers the production of cAMP which in turn stimulates PKA to 
phosphorylate Ser133 of CREB (Altarejos and Montminy, 2011; Mayr and Montminy, 2001; 
Montminy, 1997). This phosphorylated CREB together with its coactivator, the 
transcriptional coactivator of regulated CREB activity 2 (TORC2) (Koo et al., 2005) then 
binds to the cAMP-responsive element (CRE) in the promoters of PC, PEPCK and G6Pase 
genes and stimulate their transcription.  
Under fasting conditions, FoxO also binds to its responsive element known as the insulin-
responsive element (IRE) [(T/C)(G/A)AAACAA] in the promoters of PEPCK and G6Pase 
genes and stimulate their expression (Barthel et al., 2005; Nakae et al., 2008). Combined 
actions of CREB and FoxO result in the robust stimulation of gluconeogenic pathway. 
However, when the level of extracellular glucose is high and the level of insulin is high, the 
gluconeogenic rate is inhibited. As the result of insulin signaling, Akt phosphorylates FoxO 
protein at Thr24, Ser256 and Ser319 residues (Barthel et al., 2005; Nakae et al., 2008), 
preventing its entry to the nucleus thus inhibiting transcription of PEPCK and G6Pase genes 
(Zhang et al., 2006). Furthermore Akt also phosphorylates TORC2 via another kinase, SIK2, 
at Ser 171 residue, inhibiting its entry to the nucleus (Dentin et al., 2007; Koo et al., 2005). 
This in turn prevents transcriptional activation of PC, PEPCK and G6Pase genes. In 
summary insulin inhibits hepatic gluconeogenesis by inhibiting the entry of FoxO and 
TORC2 to the nucleus, thereby preventing transcriptional activation of gluconeogenic 
enzyme genes. 
6.2.4 Coordinate control of glycolysis and fatty acid synthesis  
Excess glucose is not only stored as glycogen in the liver but is also stored as fat through the 
de novo fatty acid synthesis. Insulin stimulates this effect by stimulating the glycolytic 
pathway through the increased expression of some glycolytic enzymes including 
glucokinase and L (liver)-type pyruvate kinase. This allows the production of acetyl-CoA 
which subsequently enters TCA cycle. A high rate of acetyl-CoA oxidation in the 
mitochondria accelerates the export of citrate from mitochondria to cytoplasm where it is 
oxidatively decarboxylated back to oxaloacetate and acetyl-CoA by an ATP-citrate lyase. 
Acetyl-CoA is converted to malonyl-CoA by the first rate-limiting step enzyme of 
lipogenesis, namely the acetyl-CoA carboxylase (ACC). Malonyl-CoA formed by the activity 
of ACC are condensed together to form fatty acyl-CoA in the cytoplasm. Insulin is able to 
increase both glycolysis and de novo fatty acid synthesis by stimulating the expression of two 
transcription factors, namely the sterol regulatory element binding protein 1c (SREBP1c) and 
the carbohydrate responsive element binding protein (ChREBP) (Dentin et al., 2005; 
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Desvergne et al., 2006). SREBP1c binds to the promoters of glucokinase, acetyl-CoA 
carboxylase and fatty acid synthase genes while ChREBP binds to the promoters of L-type 
pyruvate kinase, ATP-citrate lyase, acetyl-CoA carboxylase and fatty acid synthase genes 
(Postic et al., 2007; Towle et al., 1997). The coordinate regulation of glycolysis, citrate export 
and de novo fatty acid synthesis by insulin through the use of ChREBP and SREBP1c 
transcription factors allows fuel partitioning toward fat storage in hepatocytes. 
Insulin can also stimulate glycolysis through the stimulation of one of glycolytic enzymes, 
i.e. phosphofructokinase 1 (PFK1) activity. PFK1 phosphorylates glucose-6-phosphate to 
fructose-1,6-bisphosphate thus increasing the level of this intermediate for the glycolytic 
pathway. Fructose-2,6-bisphosphate is an allosteric activator of PFK1 while it is an inhibitor 
of FBPaseI (Okar et al., 2001; Pilkis et al., 1995). This fructose-2,6-bisphosphate intermediate 
is produced by the bifunctional enzyme, phosphofructokinase 2/fructose bisphosphatase 2 
(PFK2/FBPase2). PFK2 converts fructose-6-phosphate to fructose-2,6-bisphosphate while 
FBPase2 converts fructose-2,6-bisphosphate back to fructose-6-phosphate. Glucagon acting 
via cAMP-dependent protein kinase phosphorylates PFK2, converting it to an inactive form, 
allowing FBPase2 to convert fructose-2,6-bisphosphate to fructose-6-phosphate. The lower 
level of fructose-2,6-bisphosphate de-represses the FBPase1 activity, promoting 
gluconeogenesis. In contrast, insulin stimulates PFK2 activity of this bifunctional enzyme 
through phosphoprotein phosphatase, dephosphorylating PFK2, converting it into a 
catalytically active form. This results in the rise of fructose-2,6-bisphosphate level which 
stimulates PFK1, promoting glycolysis (Okar et al., 2001; Pilkis et al., 1995). 
6.2.5 Triglyceride synthesis 
Similar to liver, insulin also stimulates expression of some key enzymes in glycolytic 
pathway and de novo fatty acid synthesis, resulting in the increase in the synthesis of fatty 
acids in adipose tissue. 
The dietary fat transported with chylomicrons as well as the de novo fat that is 
synthesized from liver and transported with very low density lipoprotein are taken up in 
adipose tissue. Because triglycerides cannot be readily transported to adipocytes, they 
must be first hydrolyzed to free fatty acids and glycerol by the lipoprotein lipase (LPL). 
The LPL is synthesized by adipocytes and is secreted in the circulation where it is 
associated with the extracellular matrix on the endothelial cells. After the hydrolysis of 
triglycerides by LPL, free fatty acids can now be transported across the plasma 
membrane of endothelial cells to adipocytes. Here, the monoacylglycerol acyltransferase 
and diacylglycerol acyltransferase re-esterify free fatty acids with glycerol back to 
triglycerides (Jin et al., 2002). Insulin promotes fat storage by stimulating adipocyte LPL 
activity, resulting in the uptake of dietary fat and de novo fat from liver to adipose tissue. 
The molecular mechanism by which insulin regulates LPL activity in adipocyte is not 
well defined, although there is clear evidence that insulin does not stimulate 
transcription of LPL gene (Raynolds et al., 1990; Semenkovich et al., 1989) but rather 
enhances the secretion of LPL from adipocytes to the extracellular matrix where the 
enzyme becomes active (Camps et al., 1990; Chan et al., 1988; Knutson, 2000; Nielsen et 
al., 1997). It is noted that insulin does not stimulate LPL activity in other tissues such as 
muscle and myocardium which possesses different LPL. This explains why the fat 
deposition rate is high in adipose tissue during fed period. In addition to stimulating the 
LPL activity, insulin inhibits the activity of another lipase called the hormone sensitive 
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lipase (Watt and Steinberg, 2008). Hormone sensitive lipase is inhibited when the level of 
insulin is high. However, when the level of insulin is low, which is counterbalanced by 
the high level of glucagon, hormone sensitive lipase becomes active and it hydrolyzes 
triglycerides to free fatty acids which are released to the blood circulation during 
prolonged starvation. 
6.2.6 Protein synthesis 
Another metabolic effect of insulin is protein synthesis in muscle cells. Insulin promotes 
this anabolic process through the activity of mammalian target of rapamycin (mTOR) 
which is activated by Akt. Activation of mTOR in turn regulates different steps in the 
protein synthesis including translation initiation, elongation and ribosome biogenesis 
(Proud, 2004; Proud, 2006). The initiation factor 4 (eIF4E) functions as the protein that 
recognizes the CAP structure at the 5’-end of eukaryotic mRNA thus allowing translation 
to occur in a CAP-dependent manner. During non-stimulated conditions, eIF4E is bound 
to its inhibitor protein, PHAS1 or 4E-binding protein, resulting in the suppression of 
translation initiation. However when the level of insulin is high, PHAS1 is 
phosphorylated by mTOR, causing the dissociation of eIF4E from PHAS1. This results in 
the initiation of protein synthesis in a CAP-dependent manner (Lin et al., 1994; Wang et 
al., 2005). Insulin also regulates the recognition of the methionyl tRNA (tRNAMet) to the 
initiation codon through the initiation factor, eIF2. In general, the GTP-bound eIF2 carries 
the tRNAMet to the initiation codon where the engagement between first codon and 
tRNAMet occurs, concomitant with the release of the GDP-eIF2. The GDP-eIF2 is then 
converted back to GTP-eIF2 by another initiation factor, eIF2B. During unstimulated 
conditions, GSK3 phosphorylates eIF2B, inhibiting its activity to convert GDP-eIF2 to 
GTP-eIF2, resulting in translational inhibition. However, when the level of insulin is high, 
GSK3 is phosphorylated by Akt/PKB resulting in the loss of its activity. This causes the 
de-repression of eIF2B activity, enabling it to activate eIF2B (Cohen and Frame, 2001). 
Insulin can also regulate the elongation step of protein synthesis by modulating the 
activity of elongation factor, eEF2 (Proud, 2006; Redpath et al., 1996). In general eEF2 
facilitates the translocation of ribosome along the mRNA so that the next codon can be 
engaged by the corresponding aminoacyl tRNA. This translocation process is regulated by 
the eEF2 kinase which phosphorylates Thr56 residue of eEF2, inhibiting its activity to 
translocate the ribosome to the next site. When the level of insulin is high, mTOR 
phosphorylates eEF2 kinase, allowing eEF2 to regain its activity. Insulin also promotes the 
dephosphorylation of eEF2, leading to the stimulation of polypeptide chain elongation. 
In addition to promoting initiation and elongation steps in the protein synthesis, insulin 
again stimulates ribosome biosynthesis through mTOR. mTOR phosphorylates p70 
ribosomal S6 kinase (p70) and PHAS1 as mentioned earlier. p70 subsequently 
phosphorylates S6 ribosomal protein in the 40s subunit of the ribosome, resulting in the 
biosynthesis of active ribosomes (Proud, 2004; Proud, 2006). 
Insulin has long been known to inhibit cellular protein breakdown. This is important when 
considering muscle loss in association with the increased proteolytic activity has been seen in 
the type 2 diabetic patients. Administration of insulin to the patients can reverse the muscle 
loss. Insulin inhibits protein breakdown through the inhibition of the non-ubiquitin and 
ubiquitin-mediated proteolytic activity in the proteasome (Bennett et al., 2000; Duckworth et 
al., 1994; Hamel et al., 1997). Although an insulin-degrading enzyme has been proposed to be 
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involved in this action, the exact mechanism by which this enzyme mediates the anti 
proteolytic activity of insulin remains unclear. Signaling through the Akt phosphorylation is 
also a critical step to control the ubiqutin-mediated proteolytic activity (Faridi et al., 2003). In 
muscle, two isoforms of ubiqution ligase (E3) namely the atrogin-1 (also known as MAFbx), 
MuRF-1 are transcriptionally regulated by insulin via FoxO (Sandri et al., 2004). As mentioned 
earlier, insulin stimulates phosphorylation of FoxO, inhibiting its entry to the nucleus and 
results in the transcriptional repression of artogin-1 and MuRF-1 genes. As such, the 
abundance of these two proteins is low, limiting the availability of ubiqutin-mediated 
proteolytic machinery. Furthermore insulin also inhibits the lysosomal-mediated proteolytic 
activity (autophagy) through the activation of mTOR protein (Meijer, 2008). 
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